Citius Oncology, Inc. Effective Tax Rate
Citius Oncology, Inc. (CTOR) reported Effective Tax Rate of 4.46% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2025-12-23
- Citius Oncology, Inc. effective income tax rate reconciliation, percent for fiscal 2025 was 4.46%, a 59.29% increase from fiscal 2024.
- Citius Oncology, Inc. effective income tax rate reconciliation, percent for fiscal 2024 was 2.80%, a 41.67% decline from fiscal 2023.
- Citius Oncology, Inc. effective income tax rate reconciliation, percent for fiscal 2023 was 4.80%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|
| 2025-09-30 | 4.46% 10-K · filed 2025-12-23 |
| 2024-09-30 | 2.80% 10-K · filed 2025-12-23 |
| 2023-09-30 | 4.80% 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |